CORRECTING and REPLACING Christo Georgiev Announces myPOS Store Expansion Strategy Across Europe for 2019
Sixth paragraph, first sentence of release dated October 31 2018 should read: myPOS is all set for major expansion in 2019 ...
The corrected release reads:
CHRISTO GEORGIEV ANNOUNCES MYPOS STORE EXPANSION STRATEGY ACROSS EUROPE FOR 2019
The fintech entrepreneur Christo Georgiev, founder of myPOS, a leading European card and online payments provider, has announced his plans for new store expansion in Europe, set to happen in 2019.
The news comes just weeks after the company launched its store in Milan, Italy and signals an aggressive strategy designed to bring the company’ services closer to merchants. Up until 2018 the famous fintech company, engaged in selling payment terminals and processing card payments, had online presence only. This all changed in spring 2018 when myPOS opened its first ever brick-and-mortar stone in London, the financial centre of Europe, which was quickly followed by a new location in Amsterdam, the Netherlands. In May 2018 a new company store was established in Sofia, Bulgaria as well.
The move from online presence only to physical stores is part of the new company strategy for growth driven by the company’s experience with online sales. According to the company’s founder, Mr. Christo Georgiev, in the age of the Internet online stores are often not enough.
“When it comes to selling payment terminals, having an online store is mandatory, but in many cases customers want to be able to see and experience the devices before they decide to commit their money. Having a physical location is crucial in meeting this demand. And there’s nothing better than in-person communication when a client needs help or has questions”, said Christo Georgiev.
All company stores are located in places that are easy to find and carry the spirit of the city that hosts them. For instance, the myPOS store in London is situated next to Hyde Park and Buckingham Palace, while the store in Amsterdam is located close to the centre of the city and next to channels that Amsterdam is so famous with.
myPOS is all set for major expansion in 2019 when the company plans to open no less than seven more stores across Europe. The first half of 2019 will see myPOS stores debut in Paris, Bucharest, Munich, Lisbon and Warsaw. In the second half of 2019 the company plans to open stores in Prague, the Czech Republic and in Helsinki, Finland.
The ultimate goal is to be present in all major European countries – an accomplishment that is to be achieved in the next several years.
About myPOS Europe Ltd
myPOS Europe Ltd is a licensed payments provider and processor, registered at 25 Canada Square, Level 33, Canary Wharf London E14 5LB, United Kingdom.
The myPOS package includes a smart POS device, a free myPOS account with a business VISA card and access to additional merchant services.
myPOS Europe Ltd
Head of Marketing
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CET | Pressemelding
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CET | Pressemelding
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CET | Pressemelding
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CET | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CET | Pressemelding
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 16:54:00 CET | Pressemelding
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.